Farrukh Awan, MD

Articles

Dr. Awan on the Importance of Risk Stratification in CLL

November 17th 2020

Farrukh Awan, MD, discusses the importance of risk stratification in chronic lymphocytic leukemia.

Dr. Awan on Treatment Options in the First Relapsed Setting of CLL

October 23rd 2020

Farrukh Awan, MD, discusses treatment options in the first relapsed setting in patients with chronic lymphocytic leukemia.

Dr. Awan on Remaining Questions With BTK Inhibitors and Anti-CD20 Combos in CLL

May 2nd 2020

Farrukh Awan, MD, discusses remaining questions regarding the use of BTK inhibitors and CD20-directed monoclonal antibodies in chronic lymphocytic leukemia.

Dr. Awan on Future of Combo Regimens in CLL Treatment Paradigm

April 8th 2020

Farrukh Awan, MD, discusses questions regarding combination therapies in chronic lymphocytic leukemia.

Dr. Awan on Novel Strategies Under Exploration in Relapsed/Refractory CLL

April 2nd 2020

Farrukh Awan, MD, discusses novel approaches under investigation in relapsed/refractory chronic lymphocytic leukemia.

Dr. Awan on Utilizing Acalabrutinib in CLL

March 6th 2020

Farrukh Awan, MD, discusses the utilization of acalabrutinib in patients with chronic lymphocytic leukemia.

Dr. Awan on Time-Limited Treatments in CLL

February 14th 2020

Farrukh Awan, MD, discusses the need for time-limited treatments in patients with chronic lymphocytic leukemia.

Dr. Awan on the Role of Chemotherapy in CLL

February 5th 2020

Farrukh Awan, MD, discusses the role of chemotherapy in the treatment of patients with chronic lymphocytic leukemia (CLL).

x